Feature|Videos|April 13, 2026 (Updated: April 20, 2026)

Beyond Bitterness: How Taste Science and Functional Excipients Improve Drug Performance

Key Takeaways

  • Understand why taste, and bitterness in particular, is a critical yet often underestimated factor in pharmaceutical drug development.
  • Learn what differentiates the ModulaSENSE® Bitter technology and how receptor‑based insights help reduce trial‑and‑error in formulation.
SHOW MORE

Fernanda Onofre, PhD, explains how the dsm-firmenich ModulaSENSE® Bitter platform and the functional application of vitamins as excipients are revolutionizing drug palatability and performance.

While the bitter taste of medicine is often an afterthought in development, it remains a critical barrier to patient compliance and brand success. Fernanda Onofre, PhD, Director of Global Marketing and Business Development for Pharma Biologics Solutions at dsm-firmenich, highlights how the company is addressing this challenge with ModulaSENSE® Bitter, a receptor-based technology that replaces traditional trial-and-error formulation with predictive, scientific insights. Beyond taste, she details how vitamins function as powerful excipients to stabilize formulations and mitigate risks like nitrosamine formation, providing formulators with an integrated toolkit to center patient health.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.